FDA Brief

Warning letters Drugs

FDA warning letter to

directmeds.com, Inc. dba DirectMeds

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

What happened

FDA reviewed DirectMeds' website in August 2025 and found it offered compounded semaglutide and tirzepatide. FDA said website claims—such as saying the compounded products use the same active ingredient as brand-name drugs—were false or misleading because compounded drugs are not FDA-approved. No inspection was conducted.

What FDA found

  1. Website claims for compounded semaglutide and tirzepatide are false or misleading because they imply the products are the same as FDA-approved drugs when compounded drugs are not FDA-approved.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The company introduced or delivered for introduction into interstate commerce drugs that FDA says are misbranded.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  3. Receipt in interstate commerce of misbranded drugs, and delivery or offered delivery of them, is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells DirectMeds to take immediate action, including ceasing the misleading language, and to respond in writing within 15 working days of receipt to CDER's Office of Compounding Quality and Compliance with steps taken, prevention plans, and supporting documents. If unable to complete the matter, it must explain the delay and give a completion time.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies that supply online sellers
  • marketing and compliance teams for online drug sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low